

Special Issue

Exploring Potential Diagnostic and Prognostic Salivary Biomarkers in Cancer—2nd Edition

Message from the Guest Editors

This Special Issue of *Metabolites* is planned to include current research on the use of salivary biomarkers for the diagnosis and prognosis of cancer. Its major focus is to evaluate the future perspectives of reported observations acquired from metabolomics studies that focused on evaluations of the diagnosis and prognostic tracking of salivary biomarkers for both oral and non-oral (systemic) cancers, the former including head and neck cancer, and oral cavity squamous cell and oropharyngeal squamous cell carcinomas, and the latter featuring head and squamous cell, lung, breast, pancreatic and prostate cancers, among others.

Keywords:

- salivary biomarkers
- metabolomics
- salivaomics
- diagnosis
- prognosis
- cancer

Guest Editors

Dr. Lyudmila Bel'skaya


Biochemistry Research Laboratory, Omsk State Pedagogical University, Omsk, Russia

Prof. Dr. Martin Grootveld

Leicester School of Pharmacy, Faculty of Health and Life Sciences, De Montfort University, Leicester LE1 9BH, UK

Deadline for manuscript submissions

closed (31 March 2025)



Metabolites

an Open Access Journal
by MDPI

Impact Factor 3.7
CiteScore 8.1
Indexed in PubMed



mdpi.com/si/149844

Metabolites
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
metabolites@mdpi.com

[mdpi.com/journal/
metabolites](https://mdpi.com/journal/metabolites)





Metabolites

an Open Access Journal
by MDPI

Impact Factor 3.7
CiteScore 8.1
Indexed in PubMed



[mdpi.com/journal/
metabolites](https://mdpi.com/journal/metabolites)



About the Journal

Message from the Editor-in-Chief

The metabolome is the result of the combined effects of genetic and environmental influences on metabolic processes. Metabolomic studies can provide a global view of metabolism and thereby improve our understanding of the underlying biology. Advances in metabolomic technologies have shown utility for elucidating mechanisms which underlie fundamental biological processes including disease pathology. *Metabolites* is proud to be part of the development of metabolomics and we look forward to working with many of you to publish high quality metabolomic studies.

Editor-in-Chief

Dr. Amedeo Lonardo

Internal Medicine, Ospedale Civile di Baggiovara, Azienda Ospedaliero-Universitaria, 41126 Modena, Italy

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Endocrinology, Diabetes and Metabolism)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 3.6 days (median values for papers published in this journal in the second half of 2025).